A new trading day began on Monday, with KalVista Pharmaceuticals Inc (NASDAQ: KALV) stock price up 3.19% from the previous day of trading, before settling in for the closing price of $10.03. KALV’s price has ranged from $7.30 to $15.50 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -24.26%. Meanwhile, its annual earnings per share averaged -4.83%. With a float of $38.34 million, this company’s outstanding shares have now reached $43.27 million.
Let’s determine the extent of company efficiency that accounts for 150 employees. In terms of profitability, gross margin is 46.1%, operating margin of -14231.51%, and the pretax margin is -12967.58%.
KalVista Pharmaceuticals Inc (KALV) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of KalVista Pharmaceuticals Inc is 22.42%, while institutional ownership is 89.26%. The most recent insider transaction that took place on Feb 18 ’25, was worth 25,553. In this transaction CHIEF DEVELOPMENT OFFICER of this company sold 2,601 shares at a rate of $9.82, taking the stock ownership to the 92,745 shares. Before that another transaction happened on Feb 18 ’25, when Company’s CHIEF MEDICAL OFFICER sold 3,125 for $9.82, making the entire transaction worth $30,701. This insider now owns 100,334 shares in total.
KalVista Pharmaceuticals Inc (KALV) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.91 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -4.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 29.77% during the next five years compared to -20.06% drop over the previous five years of trading.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Trading Performance Indicators
Here are KalVista Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.64, a number that is poised to hit -0.87 in the next quarter and is forecasted to reach -2.87 in one year’s time.
Technical Analysis of KalVista Pharmaceuticals Inc (KALV)
Looking closely at KalVista Pharmaceuticals Inc (NASDAQ: KALV), its last 5-days average volume was 0.45 million, which is a jump from its year-to-date volume of 0.32 million. As of the previous 9 days, the stock’s Stochastic %D was 68.85%. Additionally, its Average True Range was 0.56.
During the past 100 days, KalVista Pharmaceuticals Inc’s (KALV) raw stochastic average was set at 54.95%, which indicates a significant decrease from 69.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.44% in the past 14 days, which was higher than the 57.14% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.92, while its 200-day Moving Average is $11.10. However, in the short run, KalVista Pharmaceuticals Inc’s stock first resistance to watch stands at $10.61. Second resistance stands at $10.87. The third major resistance level sits at $11.21. If the price goes on to break the first support level at $10.02, it is likely to go to the next support level at $9.68. Should the price break the second support level, the third support level stands at $9.42.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Key Stats
With a market capitalization of 511.48 million, the company has a total of 49,418K Shares Outstanding. Currently, annual sales are 0 K while annual income is -126,640 K. The company’s previous quarter sales were 0 K while its latest quarter income was -42,270 K.
